The consensus on Vertex is simple: the cystic fibrosis franchise is a fortress, it generates the cash, and nobody is close. Let me steelman that before I poke at it. Vertex genuinely pioneered CFTR modulators, holds a deep patent estate in the area, and treats the large majority of the addressable CF population. The patent landscape confirms Vertex's outsized footprint — by assignee, it is far and away the largest holder of CFTR-modulator grants.
Now the fact that complicates the story. A fortress with one builder is different from a fortress others are learning to build near. Sionna Therapeutics' granted patent US12649750B2, "Macrocyclic compounds, compositions, and methods of using thereof" (issued June 9, 2026), sits in the CFTR-modulator space — a competitor with issued chemistry claims aimed at the same broken protein Vertex built its franchise on.
Here's why a single competing grant matters more than it looks. CFTR modulators are small molecules, and small molecules are designable-around in a way biologics often aren't. A structurally distinct compound that corrects the same channel defect doesn't necessarily infringe Vertex's composition claims. The existence of a rival's issued patent on novel CFTR chemistry is evidence that the design-around problem is being solved, not just attempted.
The cliff math here isn't a single expiry date — it's erosion. Vertex's protection is layered across many patents with staggered terms, so there's no cliff edge. But the franchise's premium economics rest on the assumption of near-total share. Every credible competitor with its own modulator chemistry chips at that assumption, and the deck rarely models share loss to a differentiated rival.
I'd like the fortress narrative to hold, because it makes Vertex easy to underwrite. But "easy to underwrite" and "correct" aren't the same thing. The honest read is that Vertex's CF lead is real and large, and simultaneously that the patent record now contains rival CFTR chemistry that didn't exist in the franchise's early years.
The grounded conclusion: don't model Vertex's CF franchise as permanent monopoly cash. Model it as a dominant position facing slow competitive entry, with the patent record as your early-warning system. When a competitor's CFTR grant issues, that's the signal to revisit the share assumption — not a reason to panic, but a reason to check the math.